Metsera Slides 1.08% as $350M Volume Tanks 67% to Rank 295th in Biotech Sell-Off

On September 23, 2025, , , ranking it 295th among active stocks. The drop follows a broader market pullback in biotech shares amid regulatory scrutiny over clinical trial data transparency.

Analysts noted reduced institutional buying activity in the stock, with key stakeholders trimming positions ahead of the FDA’s advisory panel meeting scheduled for late October. , signaling bearish sentiment among hedge funds. However, retail investor activity remains mixed, .

To run this cross-sectional strategy robustly I need a bit of clarification: 1. Stock universe • Do we look at all U.S. listed equities, a specific index (e.g., Russell 3000, S&P 500 constituents), or another universe? 2. Entry & exit price • Buy at today’s close and sell at tomorrow’s close, or buy at tomorrow’s open and sell the same day’s close? 3. Transaction costs / slippage • Should we include an assumed commission or bid-ask spread? If yes, what values? 4. Position sizing • Equal-weighted across the 500 names (i.e., 0.2 % of capital each) or value-weighted by volume/market-cap? 5. Cash-management • Un-invested cash kept in cash (0 % return) or in a risk-free proxy? Once I have these details I can plan the data pulls and run the back-test for 2022-01-03 through today.